| Dr Robert Wenzl, PHARMD | |
|
300 State St, Phillipsburg, KS 67661-1930 | |
| (785) 543-5131 | |
| (785) 543-5844 |
| Full Name | Dr Robert Wenzl |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 300 State St, Phillipsburg, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427492933 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-13642 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Wenzl, PHARMD 300 State St, Phillipsburg, KS 67661-1930 Ph: (785) 543-5131 | Dr Robert Wenzl, PHARMD 300 State St, Phillipsburg, KS 67661-1930 Ph: (785) 543-5131 |
News Archive
RnRMarketResearch.com adds "Chlamydia Trachomatis Infections - Pipeline Review, H1 2015" research to its store.
In a study designed to see if doctors who are told the exact price of expensive medical tests like MRIs in advance would order fewer of them, Johns Hopkins researchers got their answer: No.
Researchers from The University of Colorado, in collaboration with St Vincent's Institute of Medical Research in Melbourne, have identified what may be the initial target of the immune response that causes type 1 diabetes.
Ahead of World TB Day, US Food and Drug Administration Commissioner Margaret Hamburg helped public and private sector partners launch a new collaboration to significantly accelerate the development of combination treatments for tuberculosis — and replace an almost 50-year-old drug regimen. Created by the Global Alliance for TB Drug Development, the Critical Path Institute, and the Bill & Melinda Gates Foundation, the initiative could potentially reduce the time it takes to introduce new combination TB treatments from as much as a quarter century to as few as six years.
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
› Verified 3 days ago
Blade Thomas Kalleck, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 State St, Phillipsburg, KS 67661 Phone: 785-543-5131 Fax: 785-543-5844 | |
Jennifer Swenson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 State St, Phillipsburg, KS 67661 Phone: 785-543-5131 Fax: 785-543-5844 | |
Traci Eilers, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 State St, Phillipsburg, KS 67661 Phone: 785-543-5131 | |
Mrs. Alyce Estelle Peterson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 State St, Phillipsburg, KS 67661 Phone: 785-543-5131 Fax: 785-543-5844 |